The phase III ClarIDHy study randomized patients with previously treated advanced CCA harboring IDH1/2 mutations to treatment with the IDH1 inhibitor ivosidinib or placebo [42,49]. This evidence concerns the gene IDH1 and cholangiocarcinoma.